113 related articles for article (PubMed ID: 9712283)
1. Is pyrazinamide really the third drug of choice in the treatment of tuberculosis?
Koumbaniou C; Nicopoulos C; Vassiliou M; Manda-Stachouli C; Sakellariou K; Demou GS; Constantopoulos SH
Int J Tuberc Lung Dis; 1998 Aug; 2(8):675-8. PubMed ID: 9712283
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy.
Solangi GA; Zuberi BF; Shaikh S; Shaikh WM
J Coll Physicians Surg Pak; 2004 Mar; 14(3):136-8. PubMed ID: 15228843
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
4. [Hyperuricemia and arthralgia during pyrazinamide treatment].
Inoue T; Ikeda N; Kurasawa T; Sato A; Nakatani K; Ikeda T; Yoshimatsu H
Nihon Kokyuki Gakkai Zasshi; 1999 Feb; 37(2):115-8. PubMed ID: 10214039
[TBL] [Abstract][Full Text] [Related]
5. Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
Şişmanlar T; Aslan AT; Budakoğlu I
J Trop Pediatr; 2015 Oct; 61(5):351-6. PubMed ID: 26136257
[TBL] [Abstract][Full Text] [Related]
6. [Observations on the effect of PZA, EB and RFP on uric acid metabolism].
Dong SQ
Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1986 Aug; 9(4):220-2, 254. PubMed ID: 3568913
[No Abstract] [Full Text] [Related]
7. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
8. [Status quo of pyrazinamide as an antituberculosis drug].
Kameda K
Kekkaku; 1995 Jul; 70(7):445-55. PubMed ID: 7564054
[TBL] [Abstract][Full Text] [Related]
9. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide.
Taki H; Ogawa K; Murakami T; Nikai T
Kekkaku; 2008 Jul; 83(7):497-501. PubMed ID: 18709966
[TBL] [Abstract][Full Text] [Related]
11. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
Shenai S; Rodrigues C; Sadani M; Sukhadia N; Mehta A
Indian J Tuberc; 2009 Apr; 56(2):82-90. PubMed ID: 19810590
[TBL] [Abstract][Full Text] [Related]
13. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
14. Effect of drug-induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis.
Adebisi SA; Oluboyo PO; Okesina AB
Afr J Med Med Sci; 2000; 29(3-4):297-300. PubMed ID: 11714010
[TBL] [Abstract][Full Text] [Related]
15. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
16. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
17. [Re-evaluation of pyrazinamide].
Kajiki A
Kekkaku; 1994 Feb; 69(2):107-12. PubMed ID: 8126986
[TBL] [Abstract][Full Text] [Related]
18. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
19. [Pyrazinamide, hyperuricemia and gouty arthritis].
Auvergne B; Lioté R; Roucoulès J; Kuntz D
Rev Rhum Mal Osteoartic; 1988 Oct; 55(10):797. PubMed ID: 3264079
[No Abstract] [Full Text] [Related]
20. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
